These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 17089480

  • 1. The medical management of opioid dependence in HIV primary care settings.
    Lum PJ, Tulsky JP.
    Curr HIV/AIDS Rep; 2006 Nov; 3(4):195-204. PubMed ID: 17089480
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study.
    Kiriazova T, Go VF, Hershow RB, Hamilton EL, Sarasvita R, Bui Q, Lancaster KE, Dumchev K, Hoffman IF, Miller WC, Latkin CA.
    Harm Reduct J; 2020 Oct 01; 17(1):69. PubMed ID: 32998731
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
    Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE.
    Drug Alcohol Depend; 2013 Dec 01; 133(2):376-82. PubMed ID: 23916321
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward.
    Wolfe D, Carrieri MP, Shepard D.
    Lancet; 2010 Jul 31; 376(9738):355-66. PubMed ID: 20650513
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA, Friedland GH, Gourevitch MN.
    Clin Infect Dis; 2006 Dec 15; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.
    Chaudhry AA, Botsko M, Weiss L, Egan JE, Mitty J, Estrada B, Lucas GM, Woodson T, Flanigan TP, Fiellin DA, BHIVES Collaborative.
    J Acquir Immune Defic Syndr; 2011 Mar 01; 56 Suppl 1():S14-21. PubMed ID: 21317589
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Narrative review: buprenorphine for opioid-dependent patients in office practice.
    Sullivan LE, Fiellin DA.
    Ann Intern Med; 2008 May 06; 148(9):662-70. PubMed ID: 18458279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.